Edition:
United Kingdom

People: Compugen Ltd (CGEN.OQ)

CGEN.OQ on NASDAQ Stock Exchange Global Market

3.51USD
4:41pm BST
Change (% chg)

$-0.05 (-1.40%)
Prev Close
$3.56
Open
$3.54
Day's High
$3.57
Day's Low
$3.51
Volume
5,437
Avg. Vol
37,808
52-wk High
$4.30
52-wk Low
$2.00

Preminger, Michal 

Dr. Michal Preminger, Ph.D. is Director of the company. She brings to Compugen broad managerial and business experience focused on the pharma and biotech industries. At Harvard Office of Technology Development, she has negotiated a multitude of licensing and strategic alliance agreements with pharmaceutical and biotechnology companies and supported the launch of many biotechnology startups. Prior to joiningHarvardin 2005, Dr. Preminger held a number of senior executive business development and R&D positions in technology and biotechnology companies, including at Compugen, where she was a member of the management team that took the Company public inAugust 2000. Dr. Preminger is a member of the board of directors of BioArray Genetics and Israel Brain Technologies, and a member of the Scientific Advisory Board at FutuRx (a partnership between Takeda Pharmaceuticals, Johnson & Johnson and Orbimed Ventures) and Prize4Life.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --